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A B S T R A C T
Percutaneous mitral valve repair was introduced a few years ago for patients with 
symptomatic severe mitral regurgitation and can use two different approaches. The 
first approach is the edge-to-edge technique, which creates a double mitral valve ori-
fice. The second approach is mitral annuloplasty, which is achieved by introducing a 
constraining device in the coronary sinus located in the vicinity of the mitral annulus. 
Preliminary results of percutaneous mitral valve repair are encouraging and show the 
feasibility of these techniques, which though should be carefully evaluated in com-
parison with surgery and standard contemporary medical treatment.
The scope of percutaneous cardiac therapy has expanded from percutaneous coro-
nary and peripheral intervention to percutaneous valve intervention, first used in the 
mid eighties. Today mitral regurgitation represents the second most important native 
valve disease in Europe (30%) as shown by the Euro Heart Survey.1-3
When patients present with symptoms, or when there are objective signs of poor 
tolerance in patients without symptoms, surgery should be performed using as often 
as possible surgical mitral valve repair, as this treatment has shown safety, efficacy 
and good long-term results. However, real life observation, once again from the Euro 
Heart Survey, has shown that mitral valve repair is performed only 50% of the time. 
This shortfall is mostly due to a lack of expertise in performing the procedure. Finally, 
observations from the Euro Heart Survey also stress the fact that half of the patients, 
despite the presence of severe symptoms and severe mitral regurgitation, are not con-
sidered for surgery by their practising physicians.3 Thus, there is a niche for treatment 
other than surgery for high-risk patients or those denied surgery.
Percutaneous mitral valve repair was introduced only a few years ago and can use 
two different approaches.4-12 The first approach is the edge-to-edge technique, which 
creates a double mitral valve orifice replicating the surgical intervention pioneered 
by Professor Alfieri.4 This technique is very demanding since it requires transseptal 
catheterisation and sophisticated collaboration between the echocardiographist and 
interventionist to catch the valve at the appropriate moment and location. Preliminary 
clinical results obtained in over 100 patients suggest that in expert hands the feasibility 
of the technique is high (80-90%) and the degree of mitral regurgitation can be reduced 
to mild in two-thirds of cases. In addition, the risk is low, once again, in experienced 
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centres. In patients where the procedure was successful, two-
thirds of the cases remained event-free after three years. Thus 
these data, even if only preliminary, are encouraging.
The second possible approach is mitral annuloplasty, 
which is achieved by introducing a constraining device in the 
coronary sinus located in the vicinity of the mitral annulus.7,8,10 
The rationale here is that ring annuloplasty is almost always 
combined with other procedures during surgical interventions 
on the mitral valve. More than ten devices have been designed 
and three are currently being studied. They share common 
technical features: distal fixation and proximal fixation in 
the coronary sinus and a bridge between these two fixating 
elements. Here the procedure is easier since it only requires 
a catheterisation of the coronary sinus. Preliminary results 
from the EVOLUTION study in 60 patients show here again 
high feasibility (90%) and good safety profiles since almost 
80% of the patients experienced no complications within 90 
days. Very preliminary efficacy data suggest a reduction in the 
degree of regurgitation.
Clearly at the present stage these two approaches do not 
yet reach the standard of the multiple surgical techniques 
that make the success of surgical mitral valve repair. The 
annuloplasty technique could be potentially used in patients 
with functional mitral regurgitation, while the edge-to-edge 
technique could be used in selected patients with degenerative 
mitral regurgitation.
The potential clinical indications of the new percutaneous 
techniques are represented by the vast group of patients with 
contraindications or judged to be at very high risk for surgery. 
Before considering extending the application of these tech-
niques to other patients, trials should be performed in order 
to answer 3 major questions: how much are we ready to lose in 
terms of efficacy by going percutaneously as opposed to surgi-
cally? Secondly, how much are we ready to risk in patients who 
have not yet reached surgical indication? And finally, will the 
performance of this percutaneous intervention compromise 
subsequent treatment possibilities? Many devices are currently 
being studied or are at the experimental stage: suture based 
direct annuloplasty, percutaneous mitral valve replacement, 
or transpericardial left ventricular remodelling.
In conclusion, the first steps of percutaneous mitral valve 
repair have been taken in almost 300 patients and show the 
feasibility of this technique suggesting also a reduction in the 
degree of mitral regurgitation. Today, we are at the stage of 
evaluation and the research should be carefully evaluated in 
comparison with surgery and standard contemporary medical 
treatment including cardiac resynchronisation. Trials such as 
EVEREST II, EVOLUTION II, and AMADEUS are under-
way. The development of these new techniques will require 
close collaboration among engineers, interventionalists, imag-
ing specialists, and surgeons.
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